{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:50:16Z","timestamp":1793407816223,"version":"4.5.0"},"reference-count":218,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["HLCA2024"],"award-info":[{"award-number":["HLCA2024"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["HLCA2022"],"award-info":[{"award-number":["HLCA2022"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006510","name":"Duke University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016017","name":"Duke-NUS Medical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016017","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.phrs.2025.107770","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T17:21:47Z","timestamp":1746724907000},"page":"107770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges"],"prefix":"10.1016","volume":"216","author":[{"given":"Zhi Dong","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxiao","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Pop\u0142awska-Domaszewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kallol Ray","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eng King","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.phrs.2025.107770_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.it.2008.05.002","article-title":"Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression","volume":"29","author":"Gao","year":"2008","journal-title":"Trends Immunol."},{"issue":"9533","key":"10.1016\/j.phrs.2025.107770_bib2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","article-title":"Alzheimer's disease","volume":"368","author":"Blennow","year":"2006","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.phrs.2025.107770_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2174\/157015906776359577","article-title":"Neuronal cell death in Alzheimer's disease and a neuroprotective factor, humanin","volume":"4","author":"Niikura","year":"2006","journal-title":"Curr. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107770_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.nic.2011.11.003","article-title":"The molecular pathology of Alzheimer's disease","volume":"22","author":"Harrington","year":"2012","journal-title":"Neuroimaging Clin. N. Am."},{"issue":"1","key":"10.1016\/j.phrs.2025.107770_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13024-020-00391-7","article-title":"Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease","volume":"15","author":"Guo","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.phrs.2025.107770_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102113","article-title":"Recent advancement in therapeutic strategies for Alzheimer\u2019s disease: insights from clinical trials","volume":"92","author":"Khan","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.phrs.2025.107770_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1206572","article-title":"Current and future therapeutic strategies for Alzheimer's disease: an overview of drug development bottlenecks","volume":"15","author":"Peng","year":"2023","journal-title":"Front Aging Neurosci."},{"issue":"1","key":"10.1016\/j.phrs.2025.107770_bib8","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12967-024-05248-x","article-title":"Passive immunotherapy for Alzheimer\u2019s disease: challenges & future directions","volume":"22","author":"Yi","year":"2024","journal-title":"J. Transl. Med"},{"issue":"1","key":"10.1016\/j.phrs.2025.107770_bib9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40035-023-00378-6","article-title":"Role of dopamine in the pathophysiology of Parkinson\u2019s disease","volume":"12","author":"Zhou","year":"2023","journal-title":"Transl. Neurodegener."},{"issue":"8","key":"10.1016\/j.phrs.2025.107770_bib10","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","article-title":"Parkinson's disease: etiopathogenesis and treatment","volume":"91","author":"Jankovic","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"null","key":"10.1016\/j.phrs.2025.107770_bib11","first-page":"1605","article-title":"Levodopa-induced dyskinesias in Parkinson\u2019s disease: emerging treatments","volume":"9","author":"Bargiotas","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"9","key":"10.1016\/j.phrs.2025.107770_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25094643","article-title":"Tyrosine hydroxylase inhibitors and dopamine receptor agonists combination therapy for Parkinson's disease","volume":"25","author":"Yi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.phrs.2025.107770_bib13","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1080\/14656566.2016.1219337","article-title":"Advances in dopamine receptor agonists for the treatment of Parkinson's disease","volume":"17","author":"Stocchi","year":"2016","journal-title":"Expert Opin. Pharm."},{"issue":"6","key":"10.1016\/j.phrs.2025.107770_bib14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1756285609339382","article-title":"Deep brain stimulation in Parkinson's disease","volume":"2","author":"Groiss","year":"2009","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"6","key":"10.1016\/j.phrs.2025.107770_bib15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab."},{"issue":"9467","key":"10.1016\/j.phrs.2025.107770_bib16","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S0140-6736(05)61032-X","article-title":"Type 2 diabetes: principles of pathogenesis and therapy","volume":"365","author":"Stumvoll","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.phrs.2025.107770_bib17","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1083\/jcb.201810097","article-title":"Pancreatic \u03b2 cells: Gatekeepers of type 2 diabetes","volume":"218","author":"Park","year":"2019","journal-title":"J. Cell Biol."},{"issue":"5","key":"10.1016\/j.phrs.2025.107770_bib18","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/archneur.61.5.661","article-title":"Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function","volume":"61","author":"Arvanitakis","year":"2004","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.phrs.2025.107770_bib19","first-page":"1585","article-title":"Diabetes mellitus and Parkinson's disease: a systematic review and meta-analyses","volume":"11","author":"Komici","year":"2021","journal-title":"J. Park. 'S. Dis."},{"issue":"4","key":"10.1016\/j.phrs.2025.107770_bib20","first-page":"1377","article-title":"The links between diabetes mellitus and amyotrophic lateral sclerosis","volume":"42","author":"Vasta","year":"2021","journal-title":"Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107770_bib21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3233\/JHD-170253","article-title":"Huntington's disease and diabetes: chronological sequence of its association","volume":"6","author":"Montojo","year":"2017","journal-title":"J. Huntingt. 'S. Dis."},{"key":"10.1016\/j.phrs.2025.107770_bib22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/nyas.12807","article-title":"Impact of diabetes on cognitive function and brain structure","volume":"1353","author":"Moheet","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.phrs.2025.107770_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2025.107770_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108277","article-title":"Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives","volume":"239","author":"Ferrari","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.phrs.2025.107770_bib25","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.2337\/db14-0568","article-title":"Insulin action in brain regulates systemic metabolism and brain function","volume":"63","author":"Kleinridders","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2025.107770_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101234","article-title":"The brain as an insulin-sensitive metabolic organ","volume":"52","author":"Milstein","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.phrs.2025.107770_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2023.105350","article-title":"Brain insulin signaling as a potential mediator of early life adversity effects on physical and mental health","volume":"153","author":"Alberry","year":"2023","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"8","key":"10.1016\/j.phrs.2025.107770_bib28","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1007\/s12035-023-03359-y","article-title":"Type 2 diabetes (T2DM) and Parkinson's disease (PD): a mechanistic approach","volume":"60","author":"Sabari","year":"2023","journal-title":"Mol. Neurobiol."},{"issue":"12","key":"10.1016\/j.phrs.2025.107770_bib29","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.molmed.2023.09.005","article-title":"Diabetes: a tipping point in neurodegenerative diseases","volume":"29","author":"Santiago","year":"2023","journal-title":"Trends Mol. Med."},{"issue":"2","key":"10.1016\/j.phrs.2025.107770_bib30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1055\/a-2009-9755","article-title":"The correlation between diabetes mellitus and neurodegenerative diseases","volume":"240","author":"Schubert","year":"2023","journal-title":"Klin. Monbl Augenheilkd."},{"issue":"3","key":"10.1016\/j.phrs.2025.107770_bib31","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005921","article-title":"Increased risk of Parkinson disease with diabetes mellitus in a population-based study","volume":"96","author":"Yang","year":"2017","journal-title":"Medicine"},{"issue":"8","key":"10.1016\/j.phrs.2025.107770_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41582-024-00994-4","article-title":"Diabetes could hasten MCI-to-AD conversion","volume":"20","author":"Wood","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.phrs.2025.107770_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2015.00204","article-title":"Aberrant insulin signaling in Alzheimer's disease: current knowledge","volume":"9","author":"Bedse","year":"2015","journal-title":"Front Neurosci."},{"key":"10.1016\/j.phrs.2025.107770_bib34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pneurobio.2016.10.001","article-title":"Insulin resistance and Parkinson\u2019s disease: a new target for disease modification?","volume":"145-146","author":"Athauda","year":"2016","journal-title":"Prog. Neurobiol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107770_bib35","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.molmed.2013.01.002","article-title":"Shared dysregulated pathways lead to Parkinson's disease and diabetes","volume":"19","author":"Santiago","year":"2013","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.phrs.2025.107770_bib36","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fnins.2019.00868","article-title":"The relevance of insulin action in the dopaminergic system","volume":"13","author":"Fiory","year":"2019","journal-title":"Front Neurosci."},{"issue":"4","key":"10.1016\/j.phrs.2025.107770_bib37","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI59903","article-title":"Demonstrated brain insulin resistance in Alzheimer\u2019s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline","volume":"122","author":"Talbot","year":"2012","journal-title":"J. Clin. Invest"},{"issue":"5","key":"10.1016\/j.phrs.2025.107770_bib38","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00401-014-1328-5","article-title":"Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer\u2019s disease and tauopathies","volume":"128","author":"Yarchoan","year":"2014","journal-title":"Acta Neuropathol."},{"issue":"4","key":"10.1016\/j.phrs.2025.107770_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214364","article-title":"Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: a double-blinded placebo-controlled pilot study","volume":"14","author":"Novak","year":"2019","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.phrs.2025.107770_bib40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"B. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial","volume":"69","author":"Baker","year":"2012","journal-title":"Arch. Neurol."},{"issue":"19","key":"10.1016\/j.phrs.2025.107770_bib41","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1113\/JP276149","article-title":"Insulin transport across the blood\u2013brain barrier can occur independently of the insulin receptor","volume":"596","author":"Rhea","year":"2018","journal-title":"J. Physiol."},{"key":"10.1016\/j.phrs.2025.107770_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.101979","article-title":"Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease","volume":"89","author":"Nowell","year":"2023","journal-title":"Ageing Res Rev."},{"key":"10.1016\/j.phrs.2025.107770_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2018.00073","article-title":"The Role of Insulin\/IGF-1\/PI3K\/Akt\/GSK3\u03b2 Signaling in Parkinson's Disease Dementia","volume":"12","author":"Yang","year":"2018","journal-title":"Front Neurosci."},{"issue":"11","key":"10.1016\/j.phrs.2025.107770_bib44","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0006-2952(02)00996-6","article-title":"Desensitization of insulin secretion","volume":"63","author":"Rustenbeck","year":"2002","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2025.107770_bib45","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/13543784.2020.1738383","article-title":"Brain insulin resistance: role in neurodegenerative disease and potential for targeting","volume":"29","author":"H\u00f6lscher","year":"2020","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"4","key":"10.1016\/j.phrs.2025.107770_bib46","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"issue":"4","key":"10.1016\/j.phrs.2025.107770_bib47","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/pr.115.011395","article-title":"Glucagon-like peptide-1 and its class b g protein\u2013coupled receptors: a long march to therapeutic successes","volume":"68","author":"Graaf","year":"2016","journal-title":"Pharm. Rev."},{"issue":"7","key":"10.1016\/j.phrs.2025.107770_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073812","article-title":"GLP-1 receptor agonists: a new treatment in Parkinson's disease","volume":"25","author":"Kalinderi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.phrs.2025.107770_bib49","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1210\/me.2008-0025","article-title":"Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors","volume":"22","author":"Dong","year":"2008","journal-title":"Mol. Endocrinology"},{"issue":"3","key":"10.1016\/j.phrs.2025.107770_bib50","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","article-title":"Mechanisms of action of glucagon-like peptide 1 in the pancreas","volume":"113","author":"Doyle","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2025.107770_bib51","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/279530","article-title":"Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function","volume":"2011","author":"Marathe","year":"2011","journal-title":"Exp. Diabetes Res."},{"issue":"2","key":"10.1016\/j.phrs.2025.107770_bib52","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1152\/ajprenal.00394.2015","article-title":"The physiological role of glucagon-like peptide-1 in the regulation of renal function","volume":"310","author":"Farah","year":"2015","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"2","key":"10.1016\/j.phrs.2025.107770_bib53","doi-asserted-by":"crossref","first-page":"F355","DOI":"10.1152\/ajprenal.00729.2010","article-title":"Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1","volume":"301","author":"Crajoinas","year":"2011","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"4","key":"10.1016\/j.phrs.2025.107770_bib54","doi-asserted-by":"crossref","first-page":"F1010","DOI":"10.1152\/ajprenal.00028.2019","article-title":"Does glucagon-like peptide-1 induce diuresis and natriuresis by modulating afferent renal nerve activity?","volume":"317","author":"Katsurada","year":"2019","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"11","key":"10.1016\/j.phrs.2025.107770_bib55","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1210\/en.2011-1070","article-title":"Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance","volume":"152","author":"Vendrell","year":"2011","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.phrs.2025.107770_bib56","doi-asserted-by":"crossref","first-page":"E620","DOI":"10.1152\/ajpendo.00069.2016","article-title":"Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives","volume":"311","author":"Jin","year":"2016","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2025.107770_bib57","first-page":"15","article-title":"Cardiovascular benefits of native GLP-1 and its metabolites: an indicator for GLP-1-therapy strategies","volume":"8","author":"Li","year":"2017","journal-title":"Front Physiol."},{"issue":"2","key":"10.1016\/j.phrs.2025.107770_bib58","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/cvr\/cvs123","article-title":"GLP-1 and cardioprotection: from bench to bedside","volume":"94","author":"Ravassa","year":"2012","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10.1016\/j.phrs.2025.107770_bib59","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1124\/jpet.102.037481","article-title":"Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4","volume":"302","author":"Perry","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2025.107770_bib60","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov. Today"},{"issue":"9","key":"10.1016\/j.phrs.2025.107770_bib61","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection","volume":"9","author":"During","year":"2003","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.phrs.2025.107770_bib62","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection","volume":"9","author":"During","year":"2003","journal-title":"Nat. Med."},{"issue":"13","key":"10.1016\/j.phrs.2025.107770_bib63","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/WNR.0b013e32832fbf14","article-title":"Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system","volume":"20","author":"Hamilton","year":"2009","journal-title":"Neuroreport"},{"issue":"4","key":"10.1016\/j.phrs.2025.107770_bib64","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1007\/s12035-017-0550-2","article-title":"Activation of glucagon-like peptide-1 receptor promotes neuroprotection in experimental autoimmune encephalomyelitis by reducing neuroinflammatory responses","volume":"55","author":"Lee","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.phrs.2025.107770_bib65","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.freeradbiomed.2016.03.002","article-title":"Glucagon-like peptide-1 improves beta-cell antioxidant capacity via extracellular regulated kinases pathway and Nrf2 translocation","volume":"95","author":"Fern\u00e1ndez-Mill\u00e1n","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.phrs.2025.107770_bib66","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.phrs.2025.107770_bib67","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7420796","article-title":"Antidiabetic drugs in Alzheimer's disease: mechanisms of action and future perspectives","volume":"2017","author":"Femminella","year":"2017","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.phrs.2025.107770_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104615","article-title":"Glucagon-like peptide-1 suppresses neuroinflammation and improves neural structure","volume":"152","author":"Yoon","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.phrs.2025.107770_bib69","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0806720106","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","volume":"106","author":"Li","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.phrs.2025.107770_bib70","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1742-2094-5-19","article-title":"Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease","volume":"5","author":"Harkavyi","year":"2008","journal-title":"J. Neuroinflamm."},{"issue":"7","key":"10.1016\/j.phrs.2025.107770_bib71","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","volume":"14","author":"Andersen","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107770_bib72","first-page":"E458","article-title":"Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig","volume":"271","author":"Deacon","year":"1996","journal-title":"Am. J. Physiol."},{"issue":"8","key":"10.1016\/j.phrs.2025.107770_bib73","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s40261-019-00826-0","article-title":"Glucagon-like peptide-1 receptor analogues in type 2 diabetes: their use and differential features","volume":"39","author":"Lyseng-Williamson","year":"2019","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.phrs.2025.107770_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"issue":"3","key":"10.1016\/j.phrs.2025.107770_bib75","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40265-013-0172-6","article-title":"Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus","volume":"74","author":"McCormack","year":"2014","journal-title":"Drugs"},{"issue":"16","key":"10.1016\/j.phrs.2025.107770_bib76","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1517\/14656566.2013.838559","article-title":"Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus","volume":"14","author":"Forst","year":"2013","journal-title":"Expert Opin. Pharm."},{"issue":"3","key":"10.1016\/j.phrs.2025.107770_bib77","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.clinthera.2016.01.014","article-title":"Exenatide once weekly: a review of pharmacology and treatment considerations in type 2 diabetes","volume":"38","author":"Brunton","year":"2016","journal-title":"Clin. Ther."},{"key":"10.1016\/j.phrs.2025.107770_bib78","first-page":"963","article-title":"Long-acting preparations of exenatide","volume":"7","author":"Cai","year":"2013","journal-title":"Drug Des. Devel Ther."},{"issue":"9","key":"10.1016\/j.phrs.2025.107770_bib79","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1592\/phco.31.9.896","article-title":"Liraglutide: clinical pharmacology and considerations for therapy","volume":"31","author":"Sisson","year":"2011","journal-title":"Pharmacotherapy"},{"issue":"null","key":"10.1016\/j.phrs.2025.107770_bib80","first-page":"215","article-title":"Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes","volume":"3","author":"Neumiller","year":"2010","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"7","key":"10.1016\/j.phrs.2025.107770_bib81","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40262-016-0499-8","article-title":"Clinical pharmacokinetics and pharmacodynamics of albiglutide","volume":"56","author":"Br\u00f8nden","year":"2017","journal-title":"Clin. Pharm."},{"issue":"7","key":"10.1016\/j.phrs.2025.107770_bib82","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3810\/pgm.2014.11.2836","article-title":"Clinical pharmacology of albiglutide, a GLP-1 receptor agonist","volume":"126","author":"Young","year":"2014","journal-title":"Post. Med"},{"issue":"3","key":"10.1016\/j.phrs.2025.107770_bib83","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1586\/17512433.2016.1141046","article-title":"Dulaglutide (LY-2189265) for the treatment of type 2 diabetes","volume":"9","author":"Scheen","year":"2016","journal-title":"Expert Rev. Clin. Pharm."},{"issue":"9","key":"10.1016\/j.phrs.2025.107770_bib84","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s40265-021-01499-w","article-title":"A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes","volume":"81","author":"Andersen","year":"2021","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.phrs.2025.107770_bib85","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s40262-021-01025-x","article-title":"Clinical pharmacokinetics of oral semaglutide: analyses of data from clinical pharmacology trials","volume":"60","author":"Overgaard","year":"2021","journal-title":"Clin. Pharm."},{"issue":"3","key":"10.1016\/j.phrs.2025.107770_bib86","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/bcp.13135","article-title":"Population pharmacokinetics of exenatide","volume":"83","author":"Cirincione","year":"2017","journal-title":"Br. J. Clin. Pharm."},{"issue":"2","key":"10.1016\/j.phrs.2025.107770_bib87","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.regpep.2003.10.028","article-title":"Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes","volume":"117","author":"Nielsen","year":"2004","journal-title":"Regul. Pept."},{"issue":"11","key":"10.1016\/j.phrs.2025.107770_bib88","first-page":"676","article-title":"Lixisenatide (Adlyxin): a once-daily incretin mimetic injection for type-2 diabetes","volume":"42","author":"Leon","year":"2017","journal-title":"P T"},{"issue":"10","key":"10.1016\/j.phrs.2025.107770_bib89","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1517\/17460441.2014.942638","article-title":"The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus","volume":"9","author":"Christensen","year":"2014","journal-title":"Expert Opin. Drug Discov."},{"issue":"2","key":"10.1016\/j.phrs.2025.107770_bib90","first-page":"161","article-title":"Evolution of exenatide as a diabetes therapeutic","volume":"9","author":"Bhavsar","year":"2013","journal-title":"Curr. Diabetes Rev."},{"issue":"8","key":"10.1016\/j.phrs.2025.107770_bib91","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.clinthera.2008.08.006","article-title":"Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study","volume":"30","author":"Moretto","year":"2008","journal-title":"Clin. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2025.107770_bib92","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.phrs.2025.107770_bib93","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.phrs.2025.107770_bib94","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.phrs.2025.107770_bib95","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1463-1326.2010.01251.x","article-title":"A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin","volume":"12","author":"Liutkus","year":"2010","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2025.107770_bib96","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial","volume":"154","author":"Buse","year":"2011","journal-title":"Ann. Intern Med"},{"issue":"3","key":"10.1016\/j.phrs.2025.107770_bib97","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jfma.2012.02.027","article-title":"Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus","volume":"112","author":"Lu","year":"2013","journal-title":"J. Formos. Med. Assoc."},{"issue":"8","key":"10.1016\/j.phrs.2025.107770_bib98","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","article-title":"Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial","volume":"143","author":"Heine","year":"2005","journal-title":"Ann. Intern Med."},{"issue":"6","key":"10.1016\/j.phrs.2025.107770_bib99","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2337\/dc11-1935","article-title":"Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)","volume":"35","author":"Fonseca","year":"2012","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.phrs.2025.107770_bib100","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/dme.12328","article-title":"Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)","volume":"31","author":"Bolli","year":"2014","journal-title":"Diabet. Med."},{"issue":"4","key":"10.1016\/j.phrs.2025.107770_bib101","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2337\/dc16-2143","article-title":"on behalf of the GetGoal OTI. Lixisenatide therapy in older patients with type 2 diabetes inadequately controlled on their current antidiabetic treatment: the getGoal-O randomized trial","volume":"40","author":"Meneilly","year":"2017","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.phrs.2025.107770_bib102","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/dom.12121","article-title":"Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)","volume":"15","author":"Pinget","year":"2013","journal-title":"Diabetes Obes. Metab."},{"issue":"3","key":"10.1016\/j.phrs.2025.107770_bib103","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jdiacomp.2014.01.012","article-title":"Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)","volume":"28","author":"Rosenstock","year":"2014","journal-title":"J. Diabetes Complicat."},{"issue":"10","key":"10.1016\/j.phrs.2025.107770_bib104","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1463-1326.2012.01618.x","article-title":"Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)","volume":"14","author":"Seino","year":"2012","journal-title":"Diabetes Obes. Metab."},{"issue":"9","key":"10.1016\/j.phrs.2025.107770_bib105","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.2337\/dc12-2454","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.phrs.2025.107770_bib106","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.2337\/dc12-2462","article-title":"Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine: A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.phrs.2025.107770_bib107","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clinthera.2011.06.004","article-title":"Review of the therapeutic uses of liraglutide","volume":"33","author":"Ryan","year":"2011","journal-title":"Clin. Ther."},{"issue":"18","key":"10.1016\/j.phrs.2025.107770_bib108","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med Chem."},{"issue":"3","key":"10.1016\/j.phrs.2025.107770_bib109","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.12591","article-title":"Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"18","author":"Nauck","year":"2016","journal-title":"Diabetes Obes. Metab."},{"issue":"5","key":"10.1016\/j.phrs.2025.107770_bib110","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1463-1326.2008.00992.x","article-title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects","volume":"11","author":"Bush","year":"2009","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2025.107770_bib111","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2337\/dc11-1107","article-title":"Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study","volume":"35","author":"Russell-Jones","year":"2012","journal-title":"Diabetes Care"},{"issue":"9733","key":"10.1016\/j.phrs.2025.107770_bib112","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/S0140-6736(10)60406-0","article-title":"Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial","volume":"375","author":"Diamant","year":"2010","journal-title":"Lancet (Lond., Engl. )"},{"issue":"9739","key":"10.1016\/j.phrs.2025.107770_bib113","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","article-title":"Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial","volume":"376","author":"Bergenstal","year":"2010","journal-title":"Lancet (Lond., Engl. )"},{"issue":"3","key":"10.1016\/j.phrs.2025.107770_bib114","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.mayocp.2015.01.008","article-title":"Five-year efficacy and safety data of exenatide once weekly: long-term results from the duration-1 randomized clinical trial","volume":"90","author":"Wysham","year":"2015","journal-title":"Mayo Clin. Proc."},{"issue":"5","key":"10.1016\/j.phrs.2025.107770_bib115","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/jc.2010-2081","article-title":"DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes","volume":"96","author":"Blevins","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.phrs.2025.107770_bib116","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1111\/dom.13266","article-title":"Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION-7 randomized study","volume":"20","author":"Guja","year":"2018","journal-title":"Diabetes Obes. Metab."},{"issue":"7","key":"10.1016\/j.phrs.2025.107770_bib117","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":"the L-SI. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)","volume":"32","author":"Zinman","year":"2009","journal-title":"Diabetes Care"},{"issue":"9662","key":"10.1016\/j.phrs.2025.107770_bib118","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet (Lond., Engl. )"},{"issue":"3","key":"10.1016\/j.phrs.2025.107770_bib119","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)","volume":"26","author":"Marre","year":"2009","journal-title":"Diabet. Med"},{"issue":"1","key":"10.1016\/j.phrs.2025.107770_bib120","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.phrs.2025.107770_bib121","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"issue":"9683","key":"10.1016\/j.phrs.2025.107770_bib122","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet (Lond., Engl. )"},{"issue":"8","key":"10.1016\/j.phrs.2025.107770_bib123","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.2337\/dc13-2759","article-title":"Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)","volume":"37","author":"Umpierrez","year":"2014","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.phrs.2025.107770_bib124","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2337\/dc13-2761","article-title":"Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)","volume":"37","author":"Nauck","year":"2014","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.phrs.2025.107770_bib125","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2337\/dc14-1625","article-title":"Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2)","volume":"38","author":"Giorgino","year":"2015","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.phrs.2025.107770_bib126","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","article-title":"Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.phrs.2025.107770_bib127","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Ludvik","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9982","key":"10.1016\/j.phrs.2025.107770_bib128","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/S0140-6736(15)60936-9","article-title":"Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study","volume":"385","author":"Blonde","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.phrs.2025.107770_bib129","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00125-015-3795-1","article-title":"Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"59","author":"Nauck","year":"2016","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.phrs.2025.107770_bib130","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2337\/dc14-0024","article-title":"for the HSG. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin","volume":"37","author":"Ahr\u00e9n","year":"2014","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.phrs.2025.107770_bib131","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/dom.12414","article-title":"Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1\u2009year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5","volume":"17","author":"Home","year":"2015","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"10.1016\/j.phrs.2025.107770_bib132","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/dom.12382","volume":"16","author":"Reusch","year":"2014","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"10.1016\/j.phrs.2025.107770_bib133","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1007\/s00125-014-3360-3","article-title":"HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea","volume":"57","author":"Weissman","year":"2014","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.phrs.2025.107770_bib134","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S2213-8587(13)70214-6","article-title":"Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study","volume":"2","author":"Pratley","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"8","key":"10.1016\/j.phrs.2025.107770_bib135","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.2337\/dc14-0001","article-title":"Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.phrs.2025.107770_bib136","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1016\/j.phrs.2025.107770_bib137","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"Jama"},{"issue":"12","key":"10.1016\/j.phrs.2025.107770_bib138","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.phrs.2025.107770_bib139","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.phrs.2025.107770_bib140","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"10.1016\/j.phrs.2025.107770_bib141","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"10.1016\/j.phrs.2025.107770_bib142","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"10.1016\/j.phrs.2025.107770_bib143","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"10.1016\/j.phrs.2025.107770_bib144","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2017","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.phrs.2025.107770_bib145","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"10.1016\/j.phrs.2025.107770_bib146","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2025.107770_bib147","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.phrs.2025.107770_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114187","article-title":"Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics","volume":"180","author":"Salameh","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2025.107770_bib149","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/j.1471-4159.2010.06731.x","article-title":"Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells","volume":"113","author":"Li","year":"2010","journal-title":"J. Neurochem."},{"issue":"5","key":"10.1016\/j.phrs.2025.107770_bib150","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1476-5381.2012.01971.x","article-title":"Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders","volume":"166","author":"Salcedo","year":"2012","journal-title":"Br. J. Pharm."},{"issue":"3","key":"10.1016\/j.phrs.2025.107770_bib151","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/jnc.12469","article-title":"Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress","volume":"128","author":"Sharma","year":"2014","journal-title":"J. Neurochem."},{"issue":"17","key":"10.1016\/j.phrs.2025.107770_bib152","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease","volume":"31","author":"McClean","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2025.107770_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107813","article-title":"Neuroprotective and restorative properties of the GLP-1\/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease","volume":"162","author":"Salles","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2025.107770_bib154","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuropharm.2013.08.005","article-title":"Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP\/PS1 mice, a model of Alzheimer's disease","volume":"76","author":"McClean","year":"2014","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.phrs.2025.107770_bib155","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3233\/JAD-143090","article-title":"The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer's disease","volume":"46","author":"Hansen","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.phrs.2025.107770_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2019.111932","article-title":"Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5\u00d7FAD mouse model of Alzheimer's disease","volume":"370","author":"An","year":"2019","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.phrs.2025.107770_bib157","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbrc.2019.01.103","article-title":"Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3\u03b2","volume":"511","author":"Zhou","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2025.107770_bib158","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.neuroscience.2014.02.022","article-title":"Lixisenatide rescues spatial memory and synaptic plasticity from amyloid \u03b2 protein-induced impairments in rats","volume":"277","author":"Cai","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.phrs.2025.107770_bib159","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bbr.2016.10.033","article-title":"Lixisenatide attenuates the detrimental effects of amyloid \u03b2 protein on spatial working memory and hippocampal neurons in rats","volume":"318","author":"Cai","year":"2017","journal-title":"Behav. Brain Res"},{"issue":"1","key":"10.1016\/j.phrs.2025.107770_bib160","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.bbrc.2017.11.114","article-title":"Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP\/PS1\/tau mouse model of Alzheimer's disease","volume":"495","author":"Cai","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1-2","key":"10.1016\/j.phrs.2025.107770_bib161","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"GIP and GLP-1, the two incretin hormones: Similarities and differences","volume":"1","author":"Seino","year":"2010","journal-title":"J. Diabetes Invest."},{"key":"10.1016\/j.phrs.2025.107770_bib162","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bbr.2017.03.032","article-title":"A novel dual GLP-1\/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model","volume":"327","author":"Shi","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.phrs.2025.107770_bib163","doi-asserted-by":"crossref","DOI":"10.1177\/1533317520953041","article-title":"The Dual GLP-1\/GIP receptor agonist DA4-JC shows superior protective properties compared to the GLP-1 analogue liraglutide in the APP\/PS1 mouse model of Alzheimer\u2019s disease","volume":"35","author":"Maskery","year":"2020","journal-title":"Am. J. Alzheimers Dis. Other Demen"},{"key":"10.1016\/j.phrs.2025.107770_bib164","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejphar.2018.03.024","article-title":"DA5-CH, a novel GLP-1\/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP\/PS1 mouse model of Alzheimer's disease","volume":"827","author":"Cao","year":"2018","journal-title":"Eur. J. Pharm."},{"issue":"S9","key":"10.1016\/j.phrs.2025.107770_bib165","article-title":"Evaluation of liraglutide in the treatment of Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer","volume":"17","author":"Edison","year":"2021","journal-title":"S. Assoc."},{"key":"10.1016\/j.phrs.2025.107770_bib166","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","article-title":"In Alzheimer\u2019s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.phrs.2025.107770_bib167","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.bbr.2018.08.006","article-title":"Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease","volume":"356","author":"Watson","year":"2019","journal-title":"Behav. Brain Res."},{"issue":"8","key":"10.1016\/j.phrs.2025.107770_bib168","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2174\/1567205016666190913155950","article-title":"A pilot study of exenatide actions in Alzheimer's disease","volume":"16","author":"Mullins","year":"2019","journal-title":"Curr. Alzheimer Res"},{"issue":"S10","key":"10.1016\/j.phrs.2025.107770_bib169","article-title":"evoke and evoke+\u2009: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating the neuroprotective effects of semaglutide in early Alzheimer\u2019s disease. Alzheimer's & dementia: the journal of the Alzheimer","volume":"18","author":"Atri","year":"2022","journal-title":"S. Assoc."},{"issue":"12","key":"10.1016\/j.phrs.2025.107770_bib170","first-page":"8661","article-title":"Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US. Alzheimer's & dementia: the journal of the Alzheimer'","volume":"20","author":"Wang","year":"2024","journal-title":"S. Assoc."},{"issue":"3","key":"10.1016\/j.phrs.2025.107770_bib171","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.amjms.2017.05.002","article-title":"Neuroprotective effects of eexenatide in a rotenone-induced rat model of Parkinson's disease","volume":"354","author":"Aksoy","year":"2017","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.phrs.2025.107770_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2019.104583","article-title":"Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes","volume":"131","author":"Elbassuoni","year":"2019","journal-title":"Neurochem. Int."},{"issue":"7","key":"10.1016\/j.phrs.2025.107770_bib173","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","article-title":"Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease","volume":"24","author":"Yun","year":"2018","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.phrs.2025.107770_bib174","article-title":"Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease","volume":"8","author":"Chen","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2025.107770_bib175","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12640-021-00460-9","article-title":"Liraglutide regulates mitochondrial quality control system through pgc-1\u03b1 in a mouse model of Parkinson's disease","volume":"40","author":"Wu","year":"2022","journal-title":"Neurotox. Res"},{"issue":"2","key":"10.1016\/j.phrs.2025.107770_bib176","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11011-021-00879-1","article-title":"Neuroprotective effects of liraglutide against inflammation through the AMPK\/NF-\u03baB pathway in a mouse model of Parkinson's disease","volume":"37","author":"Cao","year":"2022","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.phrs.2025.107770_bib177","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.peptides.2014.08.014","article-title":"Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice","volume":"61","author":"Lennox","year":"2014","journal-title":"Peptides"},{"issue":"5","key":"10.1016\/j.phrs.2025.107770_bib178","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/14728222.2022.2079492","article-title":"Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease","volume":"26","author":"Yang","year":"2022","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.phrs.2025.107770_bib179","first-page":"523","article-title":"The novel dual GLP-1\/GIP receptor agonist DA-CH5 is superior to single GLP-1 receptor agonists in the MPTP model of Parkinson\u2019s disease","volume":"10","author":"Zhang","year":"2020","journal-title":"J. Park. 'S. Dis."},{"key":"10.1016\/j.phrs.2025.107770_bib180","article-title":"A Dual GLP-1\/GIP receptor agonist is more effective than liraglutide in the A53T mouse model of Parkinson\u2019s disease","volume":"2023","author":"Zhang","year":"2023","journal-title":"Park. \u2019S. Dis."},{"key":"10.1016\/j.phrs.2025.107770_bib181","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.neuropharm.2018.02.012","article-title":"Two novel dual GLP-1\/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease","volume":"133","author":"Feng","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2025.107770_bib182","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejphar.2017.06.029","article-title":"A novel GLP-1\/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease","volume":"812","author":"Yuan","year":"2017","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.phrs.2025.107770_bib183","article-title":"DA5-CH and semaglutide protect against neurodegeneration and reduce \u03b1-synuclein levels in the 6-OHDA Parkinson's disease rat model","volume":"2022","author":"Zhang","year":"2022","journal-title":"Park. Dis."},{"issue":"10103","key":"10.1016\/j.phrs.2025.107770_bib184","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.107770_bib185","doi-asserted-by":"crossref","DOI":"10.2139\/ssrn.4212371","article-title":"A phase II, RAndomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Parkinson's disease","author":"Hogg","year":"2022","journal-title":"SSRN Electron. J."},{"issue":"13","key":"10.1016\/j.phrs.2025.107770_bib186","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of lixisenatide in early Parkinson's disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2025.107770_bib187","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","article-title":"Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"23","author":"McGarry","year":"2024","journal-title":"Lancet Neurol."},{"issue":"10479","key":"10.1016\/j.phrs.2025.107770_bib188","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","article-title":"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial","volume":"405","author":"Vijiaratnam","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.107770_bib189","first-page":"247","article-title":"What effects might exenatide have on non-motor symptoms in Parkinson\u2019s disease: a post hoc analysis","volume":"8","author":"Athauda","year":"2018","journal-title":"J. Park. 'S. Dis."},{"issue":"3","key":"10.1016\/j.phrs.2025.107770_bib190","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/ejn.14096","article-title":"Post hoc analysis of the Exenatide-PD trial\u2014Factors that predict response","volume":"49","author":"Athauda","year":"2019","journal-title":"Eur. J. Neurosci."},{"issue":"9","key":"10.1016\/j.phrs.2025.107770_bib191","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19092505","article-title":"GLP-1 analogue liraglutide attenuates mutant huntingtin-induced neurotoxicity by restoration of neuronal insulin signaling","volume":"19","author":"Chang","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.107770_bib192","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.731483","article-title":"Liraglutide improves cognitive and neuronal function in 3-NP rat model of Huntington's disease","volume":"12","author":"Shawki","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2025.107770_bib193","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032008","article-title":"Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis","volume":"7","author":"Li","year":"2012","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.phrs.2025.107770_bib194","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-96418-0","article-title":"The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1(G93A) and TDP-43(Q331K) transgenic mouse models of ALS","volume":"11","author":"Keerie","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2025.107770_bib195","first-page":"1","article-title":"Rapid progression of amyotrophic lateral sclerosis after initiation of GLP-1 agonist: a case report","author":"Stolwyk","year":"2025","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"issue":"3-4","key":"10.1016\/j.phrs.2025.107770_bib196","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev. Diabet. Stud."},{"key":"10.1016\/j.phrs.2025.107770_bib197","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9642524","article-title":"Weight Loss in Parkinson's disease: the relationship with motor symptoms and disease progression","volume":"2018","author":"Cersosimo","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.phrs.2025.107770_bib198","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnagi.2018.00001","article-title":"Weight loss and malnutrition in patients with Parkinson's disease: current knowledge and future prospects","volume":"10","author":"Ma","year":"2018","journal-title":"Front Aging Neurosci."},{"issue":"6","key":"10.1016\/j.phrs.2025.107770_bib199","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"Astrup","year":"2012","journal-title":"Int. J. Obes."},{"issue":"3","key":"10.1016\/j.phrs.2025.107770_bib200","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jamaneurol.2015.4265","article-title":"Association between change in body mass index, unified Parkinson's disease rating scale scores, and survival among persons with parkinson disease: secondary analysis of longitudinal data from NINDS exploratory trials in parkinson disease long-term study 1","volume":"73","author":"Wills","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.phrs.2025.107770_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102339","article-title":"Reelin links apolipoprotein E4, Tau, and Amyloid-\u03b2 in Alzheimer's disease","volume":"98","author":"Yi","year":"2024","journal-title":"Ageing Res Rev."},{"issue":"3","key":"10.1016\/j.phrs.2025.107770_bib202","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrn2995","article-title":"Engaging neuroscience to advance translational research in brain barrier biology","volume":"12","author":"Neuwelt","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"issue":"8","key":"10.1016\/j.phrs.2025.107770_bib203","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2231","article-title":"The GLP-1\/GIP dual-receptor agonist DA5-CH inhibits the NF-\u03baB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01","volume":"11","author":"Lv","year":"2021","journal-title":"Brain Behav."},{"issue":"4","key":"10.1016\/j.phrs.2025.107770_bib204","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1208\/s12248-015-9719-7","article-title":"Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases","volume":"17","author":"Meredith","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.phrs.2025.107770_bib205","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jconrel.2022.09.047","article-title":"Involvement of trigeminal axons in nose-to-brain delivery of glucagon-like peptide-2 derivative","volume":"351","author":"Akita","year":"2022","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"key":"10.1016\/j.phrs.2025.107770_bib206","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jconrel.2021.06.007","article-title":"Usefulness of cell-penetrating peptides and penetration accelerating sequence for nose-to-brain delivery of glucagon-like peptide-2","volume":"335","author":"Akita","year":"2021","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"issue":"2","key":"10.1016\/j.phrs.2025.107770_bib207","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1208\/s12248-015-9854-1","article-title":"Intranasal delivery of exendin-4 confers neuroprotective effect against cerebral ischemia in mice","volume":"18","author":"Zhang","year":"2016","journal-title":"AAPS J."},{"issue":"2","key":"10.1016\/j.phrs.2025.107770_bib208","first-page":"289","article-title":"Phase IIb study of intranasal glutathione in Parkinson's disease","volume":"7","author":"Mischley","year":"2017","journal-title":"J. Park. 'S. Dis."},{"issue":"12","key":"10.1016\/j.phrs.2025.107770_bib209","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202400304","article-title":"Intranasal delivery of curcumin nanoparticles improves neuroinflammation and neurological deficits in mice with intracerebral hemorrhage","volume":"8","author":"Duan","year":"2024","journal-title":"Small Methods"},{"issue":"6","key":"10.1016\/j.phrs.2025.107770_bib210","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.4103\/1673-5374.385875","article-title":"Intranasal administration of stem cell-derived exosomes for central nervous system diseases","volume":"19","author":"Gotoh","year":"2024","journal-title":"Neural Regen. Res."},{"issue":"6","key":"10.1016\/j.phrs.2025.107770_bib211","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2174\/156720112803529828","article-title":"Anatomical and histological factors affecting intranasal drug and vaccine delivery","volume":"9","author":"Gizurarson","year":"2012","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.phrs.2025.107770_bib212","doi-asserted-by":"crossref","DOI":"10.3390\/polysaccharides6010006","article-title":"Polysaccharides: new frontiers for nasal administration of medicines","author":"Clementino","year":"2025","journal-title":"Polysaccharides"},{"key":"10.1016\/j.phrs.2025.107770_bib213","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jconrel.2023.11.033","article-title":"Targeted delivery of hybrid nanovesicles for enhanced brain penetration to achieve synergistic therapy of glioma","volume":"365","author":"Wang","year":"2024","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"issue":"6","key":"10.1016\/j.phrs.2025.107770_bib214","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s41591-021-01391-w","article-title":"Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial","volume":"27","author":"Saxena","year":"2021","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.phrs.2025.107770_bib215","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2169\/internalmedicine.2489-18","article-title":"Dopamine transporter imaging in Parkinson disease: progressive changes and therapeutic modification after anti-parkinsonian medications","volume":"58","author":"Ikeda","year":"2019","journal-title":"Intern. Med."},{"issue":"1","key":"10.1016\/j.phrs.2025.107770_bib216","doi-asserted-by":"crossref","first-page":"13s","DOI":"10.2967\/jnumed.121.263195","article-title":"The role of amyloid PET in imaging neurodegenerative disorders: a review","volume":"63","author":"Chapleau","year":"2022","journal-title":"J. Nucl. Med.: Off. Publ., Soc. Nucl. Med."},{"issue":"1","key":"10.1016\/j.phrs.2025.107770_bib217","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26010389","article-title":"The \u03b1-synuclein seeding amplification assay for Parkinson's disease","volume":"26","author":"Yi","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.107770_bib218","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101615","article-title":"QEEG indices are associated with inflammatory and metabolic risk factors in Parkinson's disease dementia: an observational study","volume":"52","author":"Liu","year":"2022","journal-title":"EClinicalMedicine"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825001951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825001951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:44:25Z","timestamp":1778795065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825001951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":218,"alternative-id":["S1043661825001951"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107770","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107770","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107770"}}